explore -WSS

explore

author：fashion 2025-10-01 00:47:23 - browse：16627

insulin biosimilar — The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. Jacquelyn Martin/AP

A group representing clinical labs across the country sued the Food and Drug Administration on Wednesday over the agency’s plan to actively regulate lab-developed tests.

The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. When the FDA finalized its test regulation plan last month, several experts said it was only a matter of time until someone in the lab industry sued.

Tests made in labs have historically gone unregulated by the FDA, as the agency considered them low-risk when it started regulating medical devices in 1976. But the tests have since become more numerous and complex, and the regulatory gray area enabled unreliable tests to thrive and harm patients. Infamous examples include Theranos’ blood tests, as well as misleading prenatal genetic tests from a range of companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Medicare Advantage enrollment hits roughly 33.4 million

leisure time

WSS

Startling documents reveal new facets of Sacklers' opioid empire

Do more moles mean more problems? Not so, says new study

FDA warns medical device makers about rise in fabricated data

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Focused ultrasound for uterine fibroids: an uphill battle

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

entertainment

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

entertainment

DIEP, the 'gold standard' of breast reconstruction, is under threat

New study raises questions about niacin and heart health

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Insmed lung disease drug hits target in key Phase 3 trial

Dobbs anniversary: the lost opportunity of abortion as health care

New CMS data security rules will hurt Medicare, Medicaid research

The high cost of giving birth even with insurance

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Malaria cases in Florida and Texas: Here’s what you need to know

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

hotspot

Medicare Advantage enrollment hits roughly 33.4 million

Abridge raises $150m as clinical notes automation market heats up

Akili, maker of video game for ADHD, to be acquired for 34 million

AI used to predict Covid

Hospitals are piloting generative AI tools as regulators play catch

Biohaven protein

explore

leisure time

focus

hotspot